

H K E c a e a d C e a L e d a d T e S c E c a e H K
 L e d a e e b e c e a c e e , a e
 e e e a a a c c a c c e e e a d e e d c a a a b
 a e e a e e a e a c e e e a
 a e c e a c e e .



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT
“EXARANE” OBTAINS APPROVAL FROM
NEW ZEALAND

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Company's subsidiary, Hepalink (New Zealand) Limited ("Hepalink NZ"), has obtained approval from the New Zealand Medicines and Medical Devices Centre ("MDC") for the registration of Exarane (Exarane Tablets) in New Zealand.

The Company's Board of Directors (the "Board") has approved the registration of Exarane (Exarane Tablets) in New Zealand. The Board also approved the Company's subsidiary, Hepalink NZ, to enter into a license agreement with the MDC for the registration of Exarane (Exarane Tablets) in New Zealand.

DETAILS OF THE LICENSE

- (I) Exarane (Exarane Tablets) 20mg, 40mg, 60mg, 80mg, 100mg, 120mg, 150mg
- (II) Dose: 20mg, 40mg, 60mg, 80mg, 100mg, 120mg, 150mg
- (III) Strengths: 20mg/0.2mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/1mL, 120mg/0.80mL, 150mg/1mL

